ClinicalTrials.gg
RecruitingNCT04372277Updated May 4, 2020

Taltz in Combination With Enstilar for Psoriasis

A Phase 4 interventional study of Enstilar in Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-04.

Sponsored by Psoriasis Treatment Center of Central New Jersey · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2021, 5 years 8 months ago, but the record still lists the study as recruiting.
  • Started Apr 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey — 5 open to participants now, 5 under way, none of them phase 3. Psoriasis · Psoriasis Treatment Center of Central New Jersey.

Planned enrollment
7th of 12
25 · median 27
Started
2020
with 1 other
Phase 4
11 of 13
4 open now
Registered
11th of 13
by date

Among the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 11 in phase 4, and was the 11th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, or all of them as a file.
02

Study summary

Enstilar in combination with Taltz for plaque psoriasis.

Read the detailed description

A single center study of 25 subjects to assess the addition of Enstilar Foam in patients receiving Taltz for ≥ 24 weeks with BSA between 3% and 8%.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adult ≥ 18 years of age;
  • Diagnosis of chronic plaque-type
  • Body Surface Area between 3%-8%.
  • Patient has been treated with Taltz for a minimum of 24 weeks
  • Females of (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use one of the approved options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.
  • Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination
  • Able and willing to give written prior to performance of any study-related procedures.

Exclusion criteria

Exclusion Criteria

-˂3% or >8% BSA

  • Patient not receiving Taltz, or receiving Taltz \<24 weeks
  • Any condition, which would place the subject at unacceptable risk if he/she were to participate in the study.
  • Pregnant or breast feeding, or considering becoming pregnant during the study.
  • Use of any drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
  • Use of oral systemic medications for the treatment of psoriasis within 4 weeks.
  • Patient used other topical therapies to treat within 2 weeks of the Baseline Visit.
  • Patient received UVB phototherapy within 2 weeks of Baseline.
  • Patient received PUVA phototherapy within 4 weeks of Baseline.
  • Patient has a known to the of Enstilar® as stated in the label.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Enstilar

    Enstilar foam

    Drug: Enstilar

Interventions

  • DrugEnstilar

    topical Enstilar foam

06

What researchers measure

Primary outcomes

  1. Body Surface Area 0 or 1

    Body surface area where 1 palm is equivalent to 1%. Endpoint will evaluate number of patiens who achieve body surface are 0 or 1.

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
    Recruiting
    • Elise Nelson · Contactenelson@windsordermatology.com · 609-443-4500
    • Jerry Bagel, MD · Principal investigator
    • David Nieves, MD · Sub investigator
    • Wendy Myers, MD · Sub investigator
    • Alexa Hetzel, PA-C · Sub investigator
    • Brianna Butler, PA-C · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Mar 2021, 10 months after the start.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 10 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2020
First posted
May 4, 2020
StartActual
Apr 28, 2020
Primary completionEst.
Mar 1, 2021
CompletionEst.
Mar 30, 2021
Last update
May 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04372277
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Responsible party
Sponsor
First posted
May 4, 2020
Start date
Apr 28, 2020
Primary completion
Mar 1, 2021 (estimated)
Completion
Mar 30, 2021 (estimated)
Last update
May 4, 2020

Study contacts

Jerry Bagel, MD
Contact
dreamacres1@aol.com
6094434500
Elise Nelson
Contact
enelson@windsordermatology.com
6094434500

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion